Introduction

Abnormal liver tests are common in people with inflammatory bowel disease (IBD) and identifying the causative aetiology can be challenging. Liver test abnormalities have increased with increasing immunomodulatory therapies. It is important that gastroenterologists have a framework to identify the cause of abnormal liver tests and assess individualised risk to benefit, in particular in the context of medical therapies for IBD.

Biographies

Dr Varinder Athwal

Dr Varinder Athwal is a hepatologist at Manchester University NHS Foundation Trust Hospitals and a Senior Lecturer with the University of Manchester.

Dr Ankur Srivastava

Dr Ankur Srivastava is a Consultant Gastroenterologist and Hepatologist at Southmead Hospital, North Bristol Trust. Having graduated from the University of Bristol, he completed his postgraduate training in the North East London training programme and completed his PhD at University College London. Dr Srivastava developed an interest in early detection of chronic liver disease and non-invasive liver fibrosis markers.

Dr Srivastava is on the BSG Liver committee, and BSG Education committee. He has recently been involved in the BSG/ BASL NAFLD guidelines and was a sub-chair for the BSG/ BASL guidelines for patients with alcohol related liver disease.